653
Views
4
CrossRef citations to date
0
Altmetric
Research Paper

A phase Ⅱ, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine

, , , , , , , & show all
Pages 2641-2648 | Received 23 Nov 2019, Accepted 16 Mar 2020, Published online: 29 Apr 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Anna Lisa Ong-Lim, Georgi Shukarev, Mitzi Trinidad-Aseron, Delia Caparas-Yu, Astrid Greijer, Michel Duchene, Gert Scheper, Vitalija van Paassen, Mathieu Le Gars, Conor P. Cahill, Hanneke Schuitemaker, Macaya Douoguih & Jeanne-Marie Jacquet. (2022) Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. Human Vaccines & Immunotherapeutics 18:5.
Read now

Articles from other publishers (2)

Emmanuel J. Vidor & John F. Modlin. 2023. Plotkin's Vaccines. Plotkin's Vaccines 890 913.e14 .
Huakun Lv, Xuejiao Pan, Hui Liang, Yaping Chen, Ying Wang, Fuxing Chen, Linzhi Shen & Yu Hu. (2022) A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China. Vaccines 10:2, pages 319.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.